Introduction:
The global cell and gene therapy market is experiencing rapid growth as innovative treatments continue to emerge. According to industry reports, the market is expected to reach $10 billion by 2026, with a compound annual growth rate of 20%. Quality control testing laboratories play a crucial role in ensuring the safety and efficacy of these advanced therapies. Below, we highlight the top 10 global cell and gene therapy quality control testing laboratories in 2026.
Top 10 Global Cell and Gene Therapy Quality Control Testing Laboratories 2026:
1. Eurofins Scientific
– Eurofins Scientific is a leading global provider of laboratory services, with a strong focus on cell and gene therapy testing. The company has a market share of 15% in the quality control testing segment.
2. Charles River Laboratories
– Charles River Laboratories is a key player in the cell and gene therapy quality control testing space, offering a wide range of services to support the development and manufacturing of advanced therapies.
3. SGS SA
– SGS SA is a prominent player in the quality control testing market, providing comprehensive testing services for cell and gene therapies. The company has seen a steady increase in demand for its services, with a growth rate of 12% in the past year.
4. WuXi AppTec
– WuXi AppTec is a leading contract research organization that offers quality control testing services for cell and gene therapies. The company has a strong presence in the Asia-Pacific region, with a market share of 10%.
5. Lonza Group
– Lonza Group is a major player in the cell and gene therapy market, offering a range of testing services to ensure the quality and safety of advanced therapies. The company has experienced a 15% increase in demand for its services in the past year.
6. BioReliance Corporation
– BioReliance Corporation is a well-known provider of quality control testing services for cell and gene therapies. The company has a strong reputation for its expertise in testing services and has a market share of 8% in the quality control testing segment.
7. Covance Inc.
– Covance Inc. is a leading provider of contract research services, including quality control testing for cell and gene therapies. The company has seen a 10% increase in demand for its services in the past year, with a market share of 7%.
8. Catalent, Inc.
– Catalent, Inc. is a global leader in providing advanced delivery technologies and development solutions for drugs, biologics, and cell and gene therapies. The company has a market share of 6% in the quality control testing segment.
9. PPD, Inc.
– PPD, Inc. is a leading contract research organization that offers quality control testing services for cell and gene therapies. The company has a strong presence in the market, with a market share of 5%.
10. Merck KGaA
– Merck KGaA is a well-established company in the cell and gene therapy market, providing quality control testing services to ensure the safety and efficacy of advanced therapies. The company has a market share of 4% in the quality control testing segment.
Insights:
The global cell and gene therapy quality control testing market is expected to continue its rapid growth in the coming years, driven by increasing investments in research and development of advanced therapies. With the rise of personalized medicine and the development of innovative treatments, the demand for quality control testing services is expected to increase significantly. Companies that specialize in cell and gene therapy testing are likely to see a surge in demand for their services, as regulators and healthcare providers place a greater emphasis on ensuring the quality and safety of these advanced therapies. In order to stay competitive in this rapidly evolving market, companies will need to invest in cutting-edge technologies and expertise to meet the growing demand for quality control testing services.
Related Analysis: View Previous Industry Report
